SCHEMBL827996

SCHEMBL827996

Cc1cc(-c2nc(Nc3cccc(C(F)(F)F)c3)nn2CCC(=O)N(C)C)ccn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 1/20 0.45
▸ PSEN2 P49810 1/20 0.45
▸ APH1B Q8WW43 1/20 0.45
▸ NCSTN Q92542 1/20 0.45
▸ APH1A Q96BI3 1/20 0.45
▸ PSENEN Q9NZ42 1/20 0.45
▸ LMNA P02545 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ AURKA O14965 10/20 0.42
▸ TDO2 P48775 1/20 0.42
▸ IDH2 P48735 1/20 0.41
▸ SYK P43405 2/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ FLT1 P17948 1/20 0.40
▸ FLT4 P35916 1/20 0.40
▸ KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827573 0.92 AURKA (0.41) LMNARECQLAURKAIDH2SYK
SCHEMBL829454 0.90 IDH2 (0.43) LMNARECQLAURKAIDH2SYK
SCHEMBL827974 0.90 PSEN1 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL828927 0.83 MAPT (0.46) LMNARECQLIDH2CDK2GSK3B
SCHEMBL827759 0.81 TDO2 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL827982 0.80 CYP1A2 (0.39) —
SCHEMBL827754 0.79 IDH2 (0.46) LMNARECQLAURKAIDH2CDK2
SCHEMBL10185924 0.79 TRPV4 (0.47) LMNARECQLIDH2FLT1KDR
SCHEMBL827937 0.77 LMNA (0.43) LMNARECQLAURKAIDH2SYK
SCHEMBL827670 0.77 AURKA (0.46) AURKAIDH2GSK3BFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 PSEN1 1822/4885PSEN2 2084/4885APH1B 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback